CANC
Tema Oncology ETF
Price Chart
Latest Quote
$40.91
+0.57 (+1.40%)
Current Price
| Previous Close | $40.34 |
| Open | $40.25 |
| Day High | $41.27 |
| Day Low | $39.93 |
| Volume | 9,100 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.05% |
| Net Assets | $190.03M |
| Expense Ratio | 0.75% |
| Category | Health |
| Fund Family | Tema ETFs |
| Net Asset Value | $40.51 |
| Premium/Discount | 0.98% |
| Quarterly Dividend Yield | 0.05% |
| P/E Ratio | 25.73 |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $40.62 |
| SMA50 | $38.67 |
| SMA200 | $35.91 |
| RSI | 54.45 |
| ATR | 0.9531 |
| Rel Volume | 0.17 |
Performance History
| Week | -1.80% |
| Month | +10.02% |
| Quarter | +5.10% |
| 6 Months | +10.33% |
| YTD | +18.28% |
| Year | +56.03% |
| 10 Years | +1062.62% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $40.91 | 9,100 |
| 2026-07-16 | $40.51 | 8,100 |
| 2026-07-15 | $40.90 | 12,600 |
| 2026-07-14 | $40.85 | 21,500 |
| 2026-07-13 | $40.94 | 11,700 |
| 2026-07-10 | $41.66 | 23,400 |
| 2026-07-09 | $42.44 | 18,900 |
| 2026-07-08 | $41.98 | 143,100 |
| 2026-07-07 | $42.36 | 103,000 |
| 2026-07-06 | $41.64 | 22,600 |
| 2026-07-02 | $41.83 | 18,600 |
| 2026-07-01 | $40.81 | 51,600 |
| 2026-06-30 | $41.24 | 57,100 |
| 2026-06-29 | $41.33 | 48,800 |
| 2026-06-26 | $40.31 | 25,500 |
| 2026-06-25 | $39.50 | 415,400 |
| 2026-06-24 | $39.17 | 25,400 |
| 2026-06-23 | $38.71 | 21,500 |
| 2026-06-22 | $38.09 | 33,100 |
| 2026-06-18 | $37.19 | 29,500 |
About Tema Oncology ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.